FDA Draft Guidance for the Use of Bayesian Methods in Clinical Trials

This Perspective discusses the draft guidance for industry that the US Food and Drug Administration released on the use of bayesian methods in testing therapeutics.

Corresponding Author: Andrew Gelman, PhD, Department of Statistics, Columbia University, New York, NY 10027 (ag389@columbia.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.